Iroko Selects Aptuit as Contract Manufacturing Partner for Phase III Lower-Dose NSAID Programs Formulated Using the SoluMatrix(TM) Nanotechnology Platform

III clinical trials. Under the services agreement, Aptuit will produce for Iroko Phase III supplies of lower dose, nanotechnology formulations for multiple nonsteroidal anti-inflammatory drugs (NSAIDs). Iroko has already completed Phase II studies for...